Eli Lilly: the Evista Project

Having ability to use resources across more effectively (transfer of human capital, utilising group’s plants, facilities and services) that would lead to creating various synergies and benefit from economies of scope.

4. Expanding the company's product line to meet a broader range of customer needs The company may gain advantage on investing in a different product line. Facing new competitors would be a challenge on the part of the company. There might be opportunities waiting for the company. It is also an additional income for the company if it becomes successful. And to meet the needs of the customers by providing new products would lead to an aggressive and healthy competition. It also helps build the economy of the country if there is new development in companies. And it also leads to high employment because there's a need to hire more employees to implement the new business activities.

The company mission statement indicates that it envisions becoming a principal pharmaceutical manufacturing corporation with a special dedication to advance innovation in medicine with the

• Also, there is a potential lack of interest in the area of product offering. The company needs to go in for new product development and product modification to cope up with the competition.

Businesses continually adapt to a changing environment to maintain their market position (Appelbaum, Habashy, Malo, & Shafiq, 2012; Biedenbacha & Soumlderholma, 2008). Change is inevitable considering the current rate of technological advancement and the growth in global competition (Appelbaum et al., 2012; Armenakis & Harris, 2009; By, 2007). Increasing competition and the need for strategic flexibility and globalization is affecting almost every organization today, regardless of size, market, focus, and so on (Jaros, 2010).

Eli Lilly & Co. lost a group of important select patents so they are now looking to compete by producing new drugs . Due to long research and development times prior to a drug hitting the market, revenue forecasts for the company are unknown. Lilly’s short-term forecast is not much clearer as “revenue for the fourth quarter of 2013 declined 2 percent to $5.80 billion largely on Cymbalta’s patent expiration, the company affirmed. Net income dropped 12 percent to $727.5 million, or 67 cents per diluted share, compared with $827.2 million, or 74 cents per share, for the year-earlier quarter” (Zhang).

The trade name given to the focused product is Ebixa by Lundbeck, the drugs common name is ?memantine?, and the active substance is memantine hydrochloride.

Competition within the industry is high and continues to grow as competitors strive to intensify their presence by offering similar

As technology continue to refine how products and services are delivered to consumers, competition among industry participants becomes more refined. Organizations that are able to keep up with changing technologies become leaders while those that are not fall behind. Mergers and acquisitions are increasing while causing small businesses to sell out or seek partnerships and cooperatives in order to remain competitive and relevant.

The change of leadership at AstraZeneca signaled a crucial change in corporate strategy. For example, funding for research and development increased to $5 billion, this action helps strengthen the company’s future outlooks (AstraZeneca, 2007). To combat the problems of pipeline flow AstraZeneca purchased two companies, Cambridge Antibody Technology and MedImmune, which specialize in biologics and vaccines (Hoover’s Inc., 2008). These companies already have drugs in the late-stages of product development and on the market which will add much needed numbers to AstraZeneca’s

All companies desire to dominate any given market without being outfought or outwitted by rivals. However, the implications of

|the industry and its challenges it is important to understand its various phases of growth so far. |

The marketplace has been dynamic and competition between companies in the same industry has been increasingly intense (Ranchhod, 2004). Having dynamic capabilities contributes to a company’s “long-term survival or competitive advantage” (Johnson et al., 2008: 84). This is especially essential

The principle products are neurosciences type, which its largest selling product currently is Zyprexa for the treatment of schizophrenia, “bipolar mania and bipolar maintenance.” Recently in 2004 it released Cymbalta,

As a science-based and patient-oriented healthcare company, we strive to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis is focused on three